Abbott Laboratories has successfully completed its $21 billion acquisition of Exact Sciences, a move aimed at enhancing its presence in personalized precision oncology. However, the company faces over 1,700 lawsuits concerning its Similac infant formula, with claims alleging serious health risks, and has not allocated financial reserves for potential losses. Despite these challenges, Abbott reported strong first quarter sales of $11.16 billion and a growth rate of 13.2% in medical devices, though analysts remain wary, reflected by a Zacks Rank of 4 (Sell) and a declining consensus estimate.
“Abbott · achieved · our earnings per share (EPS) target · first quarter”
“Abbott · completed · our acquisition of Exact Sciences · March 23, 2026”
“Abbott · acquired · Exact Sciences · March 23, 2026”
“Abbott · provided · related GAAP financial measures · not provided on a forward-looking basis”
“Abbott · procures · Exact Sciences · for $21 billion”
“Abbott · confronts · 20 cent adjusted EPS dilution · true”
“Abbott · faces · over 1,700 lawsuits · true”
“Abbott · reported Q1 2026 global sales · 11.16 billion dollars · true”
“Abbott's medical devices · posted · reported growth rate · 13.2%”
“Abbott's overall sales · originate · internationally · 61%”
“Abbott is facing · pricing pressures · in China · due to VBP programs”
“Abbott currently faces · over 1,700 lawsuits · claiming its Similac infant formula causes · necrotizing enterocolitis”